Loading
Cells have an enzyme, PP2A, that removes the growth signals cancer relies on. Cancers switch it off. Drugs that switch it back on are an unusual and largely untried approach.
PP2A is a tumour suppressor phosphatase that cancers inactivate through SET, CIP2A or subunit mutations. Small-molecule activators of PP2A (SMAPs) and the related class of phosphatase-directed compounds destabilise MYC and other oncoproteins by promoting their dephosphorylation and degradation. Activating an enzyme is harder than inhibiting one, which is why the class is underdeveloped.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and 24 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, KRAS.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.